Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations
Single-arm, open-label, multicenter phase II clinical study
NSCLC
DRUG: Neratinib tablets
IRC-assessed objective response rate (ORR), IRC-assessed objective response rate (ORR), Through study completion, an average of 1 year
ORR by investigator, ORR by investigator, Through study completion, an average of 1 year|Overall Survival (OS), Overall Survival (OS), Through study completion, an average of 1 year
Fourteen patients each had three mutation sites and 42 patients were co-enrolledï¼ŒTo evaluate the objective response rate (ORR) of neratinib Tablets in advanced NSCLC with rare EGFR mutations (including G719X, E709X in exon 18, S768I in exon 20 and L861Q in exon 21).